IQVIA HOLDINGS INC. annual report, FY2021

IQVIA Holdings Inc. — FY2021 Form 10-K

Reporting period: Fiscal year ended December 31, 2021; comparative figures are for FY2020. This is an annual report, not a standalone fourth-quarter results filing. IQVIA provides analytics, technology and clinical research services, primarily to the life sciences industry, through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Financial performance and liquidity

Metric	FY2021	FY2020
Revenue	$13.874 billion	$11.359 billion
Income from operations	$1.393 billion	$731 million
Net income attributable to IQVIA	$966 million	$279 million
Diluted EPS	$4.95	$1.43
Cash provided by operating activities	$2.942 billion	$1.959 billion
Cash and cash equivalents at year-end	$1.366 billion	$1.814 billion
Total debt principal	$12.185 billion	$12.600 billion

• Revenue increased 22.1% year over year (about 21.1% at constant currency). Income from operations rose to a 10.0% revenue margin from 6.4%; attributable net income margin was approximately 7.0%, versus 2.5%.
• Costs of revenue excluding depreciation and amortization rose to 66.5% of revenue from 66.0%, a slight deterioration in that measure. Selling, general and administrative expense declined to 14.2% of revenue from 15.7%.
• Operating cash flow increased by $983 million. Investing activities used $2.103 billion, including $1.458 billion for business acquisitions and $640 million for property, equipment and software. Financing activities used $1.235 billion. Operating cash flow less reported property, equipment and software purchases was approximately $2.302 billion.
• Year-end cash was $1.366 billion; $100 million was drawn under the $1.5 billion revolving facility, with $1.4 billion reported as available borrowing capacity. Gross debt less cash was approximately $10.8 billion. The company reported compliance with debt covenants in all material respects.
• The effective tax rate was 14.5%, down from 19.3%; 2021 included tax benefits and expenses related to U.S. international tax rules. Interest expense was $375 million, down from $416 million.

Material changes and operating drivers

• Research & Development Solutions revenue increased 31.2% to $7.556 billion, driven by clinical services and laboratory testing volume, including large COVID-19 vaccine trials. Segment profit rose 40.8% to $1.476 billion.
• Technology & Analytics Solutions revenue increased 13.9% to $5.534 billion, reflecting growth in technology, real-world and analytical services, as well as COVID-related work. Segment profit increased 19.9% to $1.458 billion.
• Contract Sales & Medical Solutions revenue increased 5.8% to $784 million; segment profit rose to $75 million from $57 million. Revenue remained below 2019’s $814 million.
• Management said clinical trial activity delayed during 2020 restarted or accelerated in 2021. The company acquired Quest Diagnostics’ 40% non-controlling interest in Q² Solutions for approximately $758 million, making it wholly owned. Acquisitions used $1.458 billion of cash, net of cash acquired.
• Research & Development Solutions contracted backlog was $24.8 billion at year-end, up from $22.6 billion. The company expected about $7.0 billion to convert to revenue in the following 12 months. Separately, remaining performance obligations were $27.2 billion, with approximately 35% expected to be recognized within 12 months; this measure differs from backlog.

Outlook, risks and unusual items

• The filing provides no specific company revenue or earnings guidance. Management expects COVID-related work to continue through 2022 and potentially into 2023 or beyond. Its cited industry forecast—not company guidance—estimates global life sciences revenue growth of 3% to 6% from 2022 through 2026.
• Management reported strong liquidity and stated available cash, operating cash flows and facility access were expected to fund operating needs, capital expenditures and debt obligations for at least the next 12 months. The company also planned to continue restructuring actions into 2022 and estimated approximately 80% of employees would work in flexible arrangements under its Future of Work program.
• Key risks include COVID-19 disruption to trials and operations; clients’ ability to terminate many research contracts on 30–90 days’ notice; backlog cancellation or delays; contract cost-estimation and change-order risk; reliance on third-party data; privacy, cybersecurity and regulatory exposure; competition, foreign exchange and labor availability; and substantial debt, variable rates and restrictive covenants.
• Clinical research revenue is recognized over time using estimated total costs to complete contracts. The auditor identified this estimation as a critical audit matter. The filing also reports $20 million of restructuring costs, a $26 million loss on extinguishment of debt, and a $758 million payment to acquire Q² Solutions’ non-controlling interest.
• IQVIA disclosed pending South Korean privacy-related litigation and appeals, and ongoing litigation with Veeva, including Veeva counterclaims seeking damages exceeding $200 million. Management said it did not expect pending legal and tax matters, individually or in aggregate, to have a material adverse effect, while acknowledging an unfavorable outcome could be material for the period resolved.
• No dividends were declared or paid in 2021. The company repurchased approximately $395 million of shares during the year; the board increased the repurchase authorization by $2.0 billion in February 2022.

Important facts for investors to verify

• Whether the strong 2021 R&D growth, including COVID-19 trial and lab work, persists as pandemic-related demand changes.
• How much of the $24.8 billion R&D backlog converts to revenue on schedule, given client cancellation rights and trial delays.
• Cash conversion and working-capital movements, including the increase in unearned income and the role of advanced billings in operating cash flow.
• Debt refinancing, interest-rate exposure and the transition from LIBOR, alongside continued covenant compliance and available revolver capacity.
• Developments in the Veeva and South Korean legal matters, and any changes in privacy rules, data access or related contingencies.
• The effect of acquisitions, share repurchases and the Q² Solutions buyout on future returns, leverage and per-share results.